Alnylam Pharmaceuticals (ALNY)

Sector:Health Care
Super Investor Stats:
Ownership count:1
Ownership rank:680
% of all portfolios:0.004%
History Portfolio Manager Activity Share change % change to portfolio
Q4  2023
Dodge & Cox Reduce 2.12% 50,800 0.01
Q2  2023
Dodge & Cox Reduce 1.44% 34,800 0.01
Q1  2023
Dodge & Cox Reduce 18.29% 541,777 0.12
Q4  2022
Dodge & Cox Reduce 2.68% 81,600 0.02
Q3  2022
Dodge & Cox Reduce 1.78% 55,000 0.02
Q2  2022
Dodge & Cox Reduce 4.64% 150,800 0.03
Q4  2021
Lee Ainslie - Maverick Capital Sell 100.00% 3,983 0.01
Q3  2021
Lee Ainslie - Maverick Capital Reduce 98.64% 288,700 0.72
Q2  2021
Lee Ainslie - Maverick Capital Reduce 63.24% 503,551 0.81
Q1  2021
Dodge & Cox Reduce 8.59% 227,669 0.04
Lee Ainslie - Maverick Capital Reduce 19.12% 188,268 0.25
Q4  2020
Dodge & Cox Reduce 0.16% 4,300 0.00
Q3  2020
Dodge & Cox Reduce 2.99% 81,800 0.02
Lee Ainslie - Maverick Capital Reduce 13.12% 146,147 0.40
Q2  2020
Dodge & Cox Reduce 11.34% 350,000 0.09
Lee Ainslie - Maverick Capital Reduce 16.88% 226,097 0.70
First Eagle Investment Management Sell 100.00% 26,500 0.01
Q1  2020
Dodge & Cox Reduce 3.52% 112,500 0.02
Lee Ainslie - Maverick Capital Reduce 40.74% 921,192 2.12
Q4  2019
Lee Ainslie - Maverick Capital Reduce 29.85% 961,916 1.61
Q3  2019
Lee Ainslie - Maverick Capital Reduce 23.92% 1,013,203 1.20
Q1  2018
Dodge & Cox Reduce 42.48% 2,077,874 0.36
Q4  2017
Dodge & Cox Reduce 11.07% 609,000 0.11
Q2  2013
Thomas Russo - Gardner Russo & Quinn Sell 100.00% 75 0.00

* "Hold Price" is the last known price at which an investor still held a security. It is the closing price of the security as of the portfolio date (quarter end). This value is only provided when a security is owned by at least two investors. In the case of reporting dates being different, a weighted average price is calculated.